Drug, device firms concerned over comparative-effectiveness studies

04/13/2009 | Wall Street Journal, The

Drugmakers and medical-device companies are concerned that studies comparing the cost effectiveness of treatments will be used to deny patients access to the best care available. "The overarching purpose of the program is to give clinicians and patients information they need to make decisions," including data on effectiveness, safety and costs, said Dr. Carolyn Clancy, director of the Agency for Healthcare Research and Quality.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC